Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and HSPPC-96 in Newly Diagnosed Glioblastoma
NCT03018288Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2017
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vitespen in glioblastoma (GBM) (3 arms), sponsored by National Cancer Institute. Primary endpoint: One-year Overall Survival Rate at 1 year. Started Sep 2017; status: terminated.
02
Drugs
vitespen
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03018288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018288.